GlassScriptPhysician profile
Myrtha Basile
NPI 1083619704
$1,671.24
in general payments reported to CMS, 2019-2025
31 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $57.95 · 2021: $82.95 · 2022: $189 · 2023: $667 · 2024: $275 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.77 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $279.50 | 2022-2024 | Myrisk |
| Abbvie INC. | $241.28 | 2023-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $135.06 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.91 | 2019-2023 | Ninlaro |
| Pfizer INC. | $95.21 | 2023-2024 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $82.40 | 2020-2024 | Enhertu, Imfinzi |
| Pharmacyclics LLC, An Abbvie Company | $69.13 | 2021-2023 | Epkinly, Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $46.07 | 2023 | |
| Seagen INC. | $41.47 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $40.43 | 2019 | |
| Celgene Corporation | $39.62 | 2023 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $33.67 | 2021 | |
| Emd Serono, INC. | $32.06 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.53 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $24.62 | 2023 | Monoferric |
| Eagle Pharmaceuticals, INC. | $22.72 | 2020 | |
| Mirati Therapeutics, INC. | $21.91 | 2023 | Krazati |
| Amgen INC. | $21.17 | 2022 | |
| Genzyme Corporation | $20.45 | 2023 | |
| Blueprint Medicines Corporation | $20.07 | 2023 | Ayvakit |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Adc Therapeutics America, INC. | $19.63 | 2023 | |
| Glaxosmithkline, LLC. | $18.29 | 2021 | |
| Aveo Pharmaceuticals, INC. | $17.56 | 2023 | Fotivda |
| Kite Pharma, INC. | $17.50 | 2022 | |
| Genentech USA, INC. | $17.42 | 2019 | |
| Daiichi Sankyo INC. | $17.35 | 2019 | |
| Taiho Oncology, INC. | $16.54 | 2024 | |
| Lilly USA, LLC | $14.62 | 2023 | Verzenio, Jaypirca, Retevmo |
| Kyowa Kirin, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myrtha Basile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.